Open Access3-Bromopyruvate alleviates the development of monocrotaline-induced rat pulmonary arterial hypertension by decreasing aerobic glycolysis, inducing apoptosis, and suppressing inflammation
Author(s) -
Jie Liu,
Wang Wang,
Lei Wang,
Xianmei Qi,
Yuhui Sha,
Ting Yang
Publication year - 2019
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000000577
Subject(s) - right ventricular hypertrophy , apoptosis , medicine , terminal deoxynucleotidyl transferase , pulmonary hypertension , intraperitoneal injection , glycolysis , h&e stain , muscle hypertrophy , inflammation , lactate dehydrogenase , saline , lung , pathology , pharmacology , immunohistochemistry , tunel assay , chemistry , biochemistry , metabolism , enzyme
Pulmonary arterial hypertension (PH) is a progressive disease with limited therapeutic options, ultimately leading to right heart failure and death. Recent findings indicate the role of the Warburg effect (aerobic glycolysis) in the development of PH. However, the effect of the glycolysis inhibitor 3-bromopyruvate (3-BrPA) on the pathogenesis of PH has not been well investigated. This study aimed to determine whether 3-BrPA inhibits PH and its possible mechanism.